skip to primary navigationskip to content

Charlotte Coles

Charlotte Coles

Dr Charlotte Coles



Graduate Students

 Dr Charlotte Coles is pleased to consider applications from prospective PhD students.

Research Interests

I lead a national portfolio of breast cancer RT studies and translational research which aims to provide breast cancer patients with the best chance of cure with least side effects:

  • IMPORT LOW (n=2018): intensity modulated radiotherapy (IMRT) and partial breast radiotherapy (PBRT) in patients at low risk of recurrence – in follow up
  • IMPORT HIGH (n=2621): dose-escalated IMRT for patients at higher risk of recurrence - in follow up
  • PRIMETIME (n=2200): Post-operative avoidance of RT in minimal risk women: patient selection using biomarkers – open to recruitment
  • NEO-RT (n=50): pre-operative breast IMRT in patients receiving neo-adjuvant hormonal treatment – in set up

Potential benefit for Patients:

  • Safe reduction of whole breast plus boost RT for high risk patients from 4.5 weeks to 3 weeks
  • Minimising side effects whilst maintaining local control with PBRT for low risk patients
  • Safe avoidance of RT for patients at very low risk of recurrence
  • Possible avoidance of mastectomy following neo-adjuvant RT and endocrine therapy
  • Development of molecular profiles to predict recurrence risk and normal tissue toxicity following RT
  • Potential Benefits for NHS:

Potential Benefits for NHS:

  •  Implementation of high quality IMRT and PBRT as standard of care
  • Use of a cost-effective predictive marker for safe RT avoidance
  • Reduction in number of fractions and RT avoidance saving the NHS >£12million/year

I am also editor of Clinical Oncology journal:


Pubmed journal articles - pubmed

Key publications

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, Bhattacharya IS, Brunt AM, Ciurlionis L, Chan C, Donovan EM, Emson MA, Harnett AN, Haviland JS, Hopwood P, Jefford ML, Kaggwa R, Sawyer EJ, Syndikus I, Tsang YM, Wheatley DA, Wilcox M, Yarnold JR, Bliss JM; IMPORT Trialists. Lancet. 2017 Sep 9;390(10099):1048-1060. doi: 10.1016/S0140-6736(17)31145-5. Epub 2017 Aug 2.

Preoperative radiation therapy: The 'new' targeted breast cancer treatment? Coles CE, Fourquet A, Poortmans P. Eur J Cancer. 2017 Apr 22;78:116-117.

Another piece in the jigsaw of accelerated partial breast irradiation. Coles CE. Lancet Oncol. 2017 Jan 13. pii: S1470-2045(17)30001-3.

Treatment of regional lymph nodes in breast cancer: Evidence in favor of radiation therapy. Poortmans PMP, Coles CE, Bernier J.  JAMA Oncology 2016. 2; 8: 989-90.

Accelerated partial breast irradiation: the new standard? Coles CE, Yarnold JR. Lancet 2016. 387; 10015: 201-2.

A randomised controlled trial of Intensity Modulated Radiotherapy (IMRT) for early breast cancer: 5-year results confirm superior overall cosmesis. Mukesh MB, Barnett GC, Wilkinson JS, Moody AM, Wilson CB, Dorling L, Chan Wah Hak C, Qian W, Twyman N, Burnet NG, Wishart GC and Coles CE. Journal of Clinical Oncology 2013. 31; 36: 4488-95.